Acquisition Context Opiant Pharmaceuticals has been acquired by Indivior, with the Opiant page no longer active. This signals a strategic alignment under Indivior and potential cross-sell opportunities for Indivior’s broader addiction and overdose treatment portfolio to Opiant's legacy customers and partners.

Nasal Delivery Focus Opiant historically pursued nasal formulations for opioid overdose reversal and addiction treatments (nasal naltrexone and nalmefene). This indicates a readiness to adopt intranasal delivery strategies and potential collaboration with partners seeking non-invasive administration platforms.

Opioid Crisis Relevance Active development projects around OPNT003 for opioid overdose reversal and OPNT002 for rapid naltrexone delivery align with high-demand markets tied to overdose prevention, treatment access, and alcohol use disorders, presenting a target for licensing, co-development, or distribution partnerships.

Modest Revenue Footprint Current revenue is in the $1–10 million range with modest funding, suggesting a need for strategic partnerships to scale manufacturing, regulatory support, and market access, potentially through Indivior’s established channels.

Small-to-Medium Scale Company size (11–50 employees) and manufacturing focus imply lean operations with agility but limited internal sales reach; opportunities exist to leverage Indivior’s sales force, manufacturing capacity, and global footprint to accelerate market penetration for key pipeline products.